We offer comprehensive process development solutions to identify and develop the most optimal process for your compounds including New Chemical Entities (NCE), advanced intermediates, and Key Starting Materials (KSM).
We keep customer's needs at the center of our planning. We understand our customer's requirements at every stage of the journey to the clinic. To meet these varying requirements, we follow a phase-appropriate process development approach. We design our processes based on customer needs. Our interdisciplinary team designs and demonstrates our capabilities in finding sustainable synthetic routes by considering the following concepts:
Reduced number of processing steps Reduced timeline for the scale-up Decreased cost by choosing the most efficient route Reduced chemical or reagent usage and waste production Avoiding expensive or difficult-to-handle raw materials Improved quality and safety profiles
Our execution operations and SOPs are very well designed to internalize the phase-appropriate delivery. Safety, Environment, Legal, Economics, and Control and Throughput (SELECT) principles are a key component of our process development strategy.
We carry out the process development at our state-of-the-art development facilities located in Hyderabad and Bangalore. This facilities are equipped to handle the development of small molecules, peptides, high potent compounds, steroids, carbohydrates and activated mPEGs. The same facility also provides formulation development, analytical method development & validation services and is equipped with a dedicated high potent lab and material generation lab with the capacities of 20L & 50L reactors for API functions.
At an early stage, our focus is to accelerate the journey for the clinic to our customers through science and innovation. Our way of execution and processes ensures agility without compromising on safety, quality and sustainability. The focus at this stage is to ensure faster turnaround time.
Leveraging our vast experience in chemistry & process development, we have a unique advantage of identifying the most important process parameters.
To minimize the risk of failure at the GMP scale, we propose to perform one demonstration batch at our non-GMP kilo lab available at our development facilities.
We have a legacy of developing 500+ molecules, several of which are in the commercial phase in highly regulated markets like the USA, Europe, Japan, etc. We follow a very robust & systematic approach to process development. Our vast manufacturing footprint allows us the flexibility to choose from a variety of unit operations suitable for product manufacturing.
We follow a QbD-based approach for process development and the first step is to identify the key starting material and process parameters that impact the specification of the product. Our supply chain team helps in sourcing the raw materials with desired quality in time. For each stage, we plan a sequence of a well-designed set of experiments (DOE) to understand and establish the sensitivity of important parameters on quality.
We typically run 15-20 experiments per stage to arrive at the most optimum process. Post completion of these studies, three consecutive lab confirmatory batches will be performed to establish the yield & quality of the product.
The processes which are identified to be challenging for scale-up, are studied in our intermediate-scale non-GMP setup at our development facilities, before moving to large-scale manufacturing.
Phase-appropriate development operations
Legacy of developing 500+ molecules
Horizontal capabilities like polymorph screening, material science, Qbd, PAT tools
Network of multi-scale R and D, NGMP, and GMP manufacturing facilities
Ability to handle various types of chemistry and technology platform
Value added services - regulatory and IP
US FDA approved R and D and manufacturing facilities
APRIL 24, 2023
Both natural and unnatural catastrophic events inflict negative consequences due to the ever-increasing interconnectedness of the global economy. Those consequences are certain to last for longer duration. e.g.; The Covid-19 pandemic is still having a negative impact on the global economy. Maintaining continuity is critical for all businesses, but perhaps no othe...Read More
The pharma industry is evolving and a demand for integrated CDMOs, which can help accelerating innovations, is part of the evolution....Read More
Our strength is built on a deep understanding of cell culture, protein chemistry and an integrated analytics platform enabling a robust, scalable and controlled process. ...Read More
Introduction: An orally-available anti-diabetic candidate that simultaneously targets all three key organs of diabetes: Pancreas, Liver and Muscles. This drug targets the two main defects seen in patients with type 2 diabetes: The pancreas by increasing insulin secretion, in a glucose-dependent manner; and the muscles and liver by decreasing the excess production...Read More
A conceptually new three-component reaction was developed to construct a six-membered fused N-heterocyclic ring affording (pyrazolo)pyrimidines/pyridines as potential inhibitors of PDE4. The reaction is catalyzed by triflic acid in acetic acid in the presence of aerial oxygen. ...Read More
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...Read More
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...Read More
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.